MarketInOut Stock Screener Log In | Sign Up

AbCellera Biologics Inc

IEX • Healthcare • Biotechnology • Quote as of 10/30/2026
AbCellera Biologics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization3,976.06 mln
Float254 mln
Earnings Date11/09/2026

Piotroski F-Score

5 / 9
Neutral

Beneish M-Score

-3.84
Highly reliable

1-Year Forecast

16.82
Strong upside

Relative Strength

78 / 100
Strongly outperforming

Debt / Equity

0.15
Very low leverage

Pre-Tax Margin

-297%
Severely loss-making

Business Description

Founded in 2012 and based in Vancouver, Canada, AbCellera Biologics works to find and build new antibody treatments for patients who currently have few good options. The company has two drugs moving through clinical trials: one non-hormonal treatment for hot flashes and night sweats, and another targeting certain immune system disorders like atopic dermatitis. AbCellera works alongside major partners including Eli Lilly, AbbVie, and Biogen to advance its research and bring new medicines to market.

Key Fundamentals

EPS-0.54
ROE-17.25
RPS0.22
ROIC-24.44
ROA-12.23
EBITDA, mln-164
EV / EBITDA-22.66
EV / EBIT-18.91
Revenue, mln66.17
EV / Revenue56.23

Quote Details

Last 12.27
Change -0.81 (-6.19%)
Open 12.65
Volume 3,621,422
Turnover 44,434,848
Average Volume 3,964,054

Financial Ratios

Pre-Tax Profit Margin-297
Leverage Ratio1.46
Current Ratio12.77
Price / Book4.39
Price / Tangible Book4.84
Debt / Equity0.15
Price / Sales58.58

Financial Strength

Altman Z-Score5.7
Piotroski F-Score 5 / 9
Beneish M-Score-3.84
1-Year Target Price16.82
Short Ratio5.65
Short % of Float12.16

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 3.81% 85 / 100   
1 Month -11.85% 20 / 100   
2 Months 134% 100 / 100   
6 Months 177% 100 / 100   
1 Year 118% 97 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog